FDA expands use of Kisqali to early stage breast cancer patients
Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.
Pharmaceutical Technology on MSN2 天
FDA expands Novartis’ Kisqali label to include early breast cancer patients
Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData ...
Kisqali wins FDA nod for breast cancer treatment: Dosage, effectiveness and side effects of ...
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...
biopharma-reporter1 天
Novartis’ Kisqali receives FDA approval to reduce the risk of breast cancer recurrence
Novartis announced this week that the FDA has approved ribociclib (marketed as Kisqali) for the treatment of people with ...
FDA expands approval of breast cancer drug Kisqali to earlier stage patients
The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to treat patients with earlier stage cancer, ...
Cure Today2 天
Kisqali Plus Aromatase Inhibitor Shows Benefits in HR+/HER2- Breast Cancer
Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free ...
pharmaphorum2 天
Lilly on alert as new Kisqali approval threatens Verzenio
Verzenio was approved for a similar adjuvant indication last year, having been used for a couple of years only in patients ...
scrippsnews2 天
Breast cancer drug Kisqali gets FDA approval to prevent cancer recurrence
The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce ...
FiercePharma3 天
Novartis heaps pressure on Lilly with broad FDA approval for Kisqali in early breast cancer
An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...
China Internet Information Center2 天
FDA aprueba nuevo tratamiento contra el cáncer de mama en etapas tempranas
La Administración de Alimentos y Medicamentos de Estados Unidos (FDA) otorgó el martes la aprobación al uso de ribociclib adyuvante (Kisqali) en combinación con un inhibidor de la aromatasa, destinado ...
Novartis’ Kisqali gets expanded FDA OK; Mene Pangalos joins Omega Funds
The FDA’s clearance could double Kisqali’s breast cancer market. Elsewhere, Novo is exploring new ways to deliver genetic ...
Novartis股票面临Kisqali专利诉讼的尾部风险 - 美银证券
周三，美银证券调整了对Novartis (NOVN:SW) (NYSE: NVS)股票的立场，将这家制药巨头的评级从买入下调至中性。该公司还修改了Novartis的目标价，将其从之前的110.00瑞士法郎下调至110.00瑞士法郎。这一评级变化是在Novartis相对于其欧洲制药同行表现出色之后做出的。 自2023年初以来，Novartis因一系列成功的III期试验和持续超出预期的盈利而备受关注， ...